Article
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Annals of the rheumatic diseases - 1 Dec 2011
Kuemmerle-Deschner Jasmin B, Hachulla E, Cartwright R, Hawkins P N, Tran T A, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, Leslie K S, Jiménez S, Morell-Dubois S, Davis N, Patel N, Widmer A, Preiss R, Lachmann H J
Abstract excerpt
OBJECTIVE: Longer-term effects of prolonged selective interleukin-1β blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date. METHODS: Adult and paediatric CAPS patients (n=166, including canakinumab-naive and pretreated patients from previous studies) received canakinumab subcutaneously 150 mg or 2 mg/kg (≤40 kg) every 8 weeks for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.